These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

620 related items for PubMed ID: 15875185

  • 1. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC, Guan Y, Soenen DR, Danishefsky SJ, Boger DL.
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
    [Abstract] [Full Text] [Related]

  • 2. Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity.
    Bacherikov VA, Chou TC, Dong HJ, Zhang X, Chen CH, Lin YW, Tsai TJ, Lee RZ, Liu LF, Su TL.
    Bioorg Med Chem; 2005 Jun 02; 13(12):3993-4006. PubMed ID: 15911312
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.
    Chou TC, Dong H, Zhang X, Tong WP, Danishefsky SJ.
    Cancer Res; 2005 Oct 15; 65(20):9445-54. PubMed ID: 16230408
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F, deMuys JM, Bouffard DY, Attardo G.
    Cancer Chemother Pharmacol; 2002 Dec 15; 50(6):490-6. PubMed ID: 12451476
    [Abstract] [Full Text] [Related]

  • 5. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.
    Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ.
    Cancer Res; 1996 Sep 15; 56(18):4171-9. PubMed ID: 8797588
    [Abstract] [Full Text] [Related]

  • 6. Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
    Bacherikov VA, Chou TC, Dong HJ, Chen CH, Lin YW, Tsai TJ, Su TL.
    Bioorg Med Chem Lett; 2004 Sep 20; 14(18):4719-22. PubMed ID: 15324894
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
    Zhu X, Sui M, Fan W.
    Anticancer Res; 2005 Sep 20; 25(3B):1953-62. PubMed ID: 16158930
    [Abstract] [Full Text] [Related]

  • 8. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC.
    Cancer Chemother Pharmacol; 2006 Nov 20; 58(5):640-53. PubMed ID: 16544145
    [Abstract] [Full Text] [Related]

  • 9. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
    Peer D, Dekel Y, Melikhov D, Margalit R.
    Cancer Res; 2004 Oct 15; 64(20):7562-9. PubMed ID: 15492283
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM.
    Cancer Chemother Pharmacol; 2008 Nov 15; 62(6):1045-54. PubMed ID: 18301895
    [Abstract] [Full Text] [Related]

  • 11. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance.
    Fu L, Liang Y, Deng L, Ding Y, Chen L, Ye Y, Yang X, Pan Q.
    Cancer Chemother Pharmacol; 2004 Apr 15; 53(4):349-56. PubMed ID: 14666379
    [Abstract] [Full Text] [Related]

  • 12. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
    Ramachandran C, Wellham LL.
    Anticancer Res; 2003 Apr 15; 23(3B):2681-90. PubMed ID: 12894558
    [Abstract] [Full Text] [Related]

  • 13. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
    Jin J, Wang FP, Wei H, Liu G.
    Cancer Chemother Pharmacol; 2005 Feb 15; 55(2):179-88. PubMed ID: 15378274
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
    Barthomeuf C, Grassi J, Demeule M, Fournier C, Boivin D, Béliveau R.
    Cancer Chemother Pharmacol; 2005 Aug 15; 56(2):173-81. PubMed ID: 15824923
    [Abstract] [Full Text] [Related]

  • 15. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ, Tian H, Joseph IB, Menon K, Frost D.
    Cancer Chemother Pharmacol; 2007 May 15; 59(6):725-32. PubMed ID: 16967299
    [Abstract] [Full Text] [Related]

  • 16. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R.
    Cancer Chemother Pharmacol; 2009 Jan 15; 63(2):201-12. PubMed ID: 18350296
    [Abstract] [Full Text] [Related]

  • 17. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
    Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, Mayer LD.
    Cancer Res; 2000 Jun 01; 60(11):2964-72. PubMed ID: 10850444
    [Abstract] [Full Text] [Related]

  • 18. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, Shi Z, Gu LQ, Yang XP, Fu LW.
    J Pharm Pharmacol; 2004 Aug 01; 56(8):1061-6. PubMed ID: 15285852
    [Abstract] [Full Text] [Related]

  • 19. Novel multidrug resistance reversal agents.
    Berger D, Citarella R, Dutia M, Greenberger L, Hallett W, Paul R, Powell D.
    J Med Chem; 1999 Jun 17; 42(12):2145-61. PubMed ID: 10377220
    [Abstract] [Full Text] [Related]

  • 20. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
    Fang W, Li Y, Cai Y, Kang K, Yan F, Liu G, Huang W.
    J Pharm Pharmacol; 2007 Dec 17; 59(12):1649-55. PubMed ID: 18053326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.